IL6 and neoplasm: Tumor- and host-derived cytokines (e.g., IL-6 family, TNF-α) increase receptor activator of nuclear factor-κ B ligand (RANKL) expression and inhibit osteoprotegerin (OPG), which drives remodeling toward osteoclastogenesis and cortical/trabecular loss [105].